$XFOR (X4 PHARMACEUTICALS) — 8-K: X4 presents September 2026 corporate deck on mavorixafor chronic neutropenia program

X4 Pharmaceuticals filed an investor presentation highlighting mavorixafor for chronic neutropenia, including the ongoing 4WARD Phase 3 study and expectations for top-line data timing. The deck also covers the organizational restructuring intended to support 4WARD execution, potential U.S. and ex-U.S. regulatory pathways, patent protection, market opportunity, and cash runway. No new financial results or updated revenue, EPS, or guidance figures were disclosed in the filing.

X4 Pharmaceuticals filed an investor presentation highlighting mavorixafor for chronic neutropenia, including the ongoing 4WARD Phase 3 study and expectations for top-line data timing. The deck also c